🍪 Our Cookies

This website uses cookies, pixel tags, and similar technologies (“Cookies”) for the purpose of enabling site operations and for performance, personalisation, and marketing purposes. We use our own Cookies and some from third parties. Only essential Cookies are used by default. By clicking “Accept All” you consent to the use of non-essential Cookies (i.e., functional, analytics, and marketing Cookies) and the related processing of personal data. You can manage your consent preferences by clicking Manage Preferences. You may withdraw a consent at any time by using the link “Cookie Preferences” in the footer of our website.

Our Privacy Notice is accessible here. To learn more about the use of Cookies on our website, please view our Cookie Notice.

Better Health kicks off talks with Blue Owl-led lender group

Share

News and Analysis

Better Health kicks off talks with Blue Owl-led lender group

Rachel Butt's avatar
Max Frumes's avatar
  1. Ayden Crosby
  2. +Rachel Butt
  3. + 1 more
•2 min read

Certain lenders to Better Health (fka Physician Partners) have started talks with the company as its earnings decline, 9fin sources say.

The talks with a lender group, led by Blue Owl, come as a number of healthcare providers are facing pressure on their profitability after the Centers for Medicare & Medicaid Services changed how patients with pre-existing conditions are risk scored. This change has led to lower revenues despite prevailing costs for the same care, as previously reported.

The Kinderhook Industries-backed primary care service provider had hired Evercore and Kirkland9fin reported in August, with lenders banding together with Davis Polk and Houlihan Lokey prior to the negotiations.

The company on 18 October saw a ratings downgrade to CCC+ from B-, as elevated operating costs squeezed its EBITDA margin to 2% in the first half of 2024, down from 8% the same period 2023, according to S&P. As of 30 June 2024, it had roughly $142.3m in cash and an $88m revolver due 2026, the credit rater said.

High medical cost ratios, capex on newly opened locations, and $7.5m annual debt amortization costs under its $750m first-lien term loan due 2028 will put the company in a free cash flow deficit until 2026, S&P said.

Still, it has no major debt maturities until 2028 and can cover expenses for the next couple of years, it said.

The company has a $600m first lien term loan and $150m incremental loan, both due 2028. 

Representatives at Better Health, Kinderhook and Blue Owl did not respond to requests for comment.

Explore our news and analysis for our latest scoops and in-depth analysis. 

What are you waiting for?

Try it out
  • We're trusted by the top 10 Investment Banks